文献速递头颈外科

局部晚期头颈癌患者接受诱导化疗后中剂量或高剂量顺铂放化疗的耳毒性研究

Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy.
PubMed 文献 · Head Neck · 2018-12-07

CONDOR研究纳入62例局部晚期头颈癌患者,比较TPF诱导化疗后顺铂100 mg/m²同步常规放疗(cis100+RT)与顺铂每周40 mg/m²同步加速放疗(cis40+ART)的耳毒性。高剂量组12例与中剂量组11例的完整听力数据可分析,高剂量组在4 kHz(z=1.98;P=.04)和8 kHz(z=2.07;P<.03)的听力损失显著多于中剂量组。结论:TPF诱导后,cis100+RT的耳毒性高于cis40+ART。

要点

  • TPF诱导后cis100+RT组在4 kHz和8 kHz听力损失显著多于cis40+ART组。
  • 高剂量组12例、中剂量组11例有完整听力数据,两组个体间变异均较大。
  • 结论:诱导TPF后,cis100+RT耳毒性高于cis40+ART。

核心结论

  • TPF诱导化疗后,cis100+RT放化疗的耳毒性高于cis40+ART放化疗。

研究设计与样本

  • CONDOR研究纳入62例局部晚期头颈癌患者,比较TPF诱导后cis100+RT与cis40+ART的耳毒性。
  • 听力检查在基线、TPF期间、放化疗开始前及治疗后1、4、8、12个月进行。

主要发现

  • 高剂量组12例、中剂量组11例有完整听力数据可分析。
  • 高剂量组在4 kHz听力损失显著多于中剂量组(z=1.98;P=.04)。
  • 高剂量组在8 kHz听力损失显著多于中剂量组(z=2.07;P<.03)。
  • 两组个体间变异均较大。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study evaluated ototoxicity in locally advanced head and neck cancer patients treated in the CONDOR study with docetaxel/cisplatin/5-fluorouracil (TPF) followed by conventional radiotherapy with concomitant cisplatin 100 mg/m2 on days 1, 22, and 43 (cis100+RT) versus accelerated radiotherapy with concomitant cisplatin weekly 40 mg/m2 (cis40+ART). METHODS: Sixty-two patients were treated in this study. Audiometry was performed at baseline, during TPF, before start of chemoradiotherapy, and 1, 4, 8, and 12 months after treatment. RESULTS: A complete dataset of audiometric data was available of 12 patients treated with high-dose cisplatin and of 11 patients treated with intermediate-dose cisplatin. Patients in the high-dose group showed significant more hearing loss than in the intermediate group at 4 kHz ([z = 1.98; P = .04] and 8 kHz [z = 2.07; P < .03]). Interindividual variation was high in both groups. CONCLUSION: After induction TPF, more ototoxicity was observed in chemoradiotherapy with cis100+RT than after chemoradiotherapy with cis40+ART.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Driessen CML, Leijendeckers J, Snik A, et al. Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy. Head Neck. 2018. PMID: 30536479. doi:10.1002/hed.25434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。